Vaccine Collaboration and Licensing Deals 2016-2026

Description

The definitive benchmark for vaccine dealmaking

Vaccine partnering is shaped by global health priorities, large-scale development programs, and collaboration between public and private sector stakeholders, with deal structures reflecting both commercial and strategic considerations.

This report provides a comprehensive and structured analysis of 880+ vaccine collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how vaccine deals are structured in practice, allowing you to:

Benchmark comparable transactions with confidence
Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
Define realistic market parameters
Clear insight into how deal terms vary by stage, technology platform, and partner profile
Support valuation and structuring decisions with evidence
Ground internal discussions in real transaction data rather than assumptions
Understand how leading companies approach dealmaking
Visibility into partner behaviour and recurring deal structures across a globally coordinated and policy-influenced landscape
Full visibility into deal structure and execution
Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

Rights granted and retained
Development and commercialization responsibilities
Financial structures and payment triggers
Key contractual provisions and protections
This level of transparency is critical to understanding how value, risk, and control are allocated within vaccine partnerships, particularly in settings involving large-scale manufacturing, distribution, and public sector engagement.
Designed for real-world BD and strategy use

The report is widely used to:

Structure and benchmark live transactions
Prepare for negotiations with well-defined market context
Evaluate partnership opportunities and counterparties
Support internal strategy with robust, defensible data
What's included
880+ vaccine collaboration and licensing deals
Financial terms, including upfronts, milestones, and royalties where disclosed
Fully searchable deal directory (by company, technology, and indication)
Direct access to SEC-filed agreements and source documents
Analysis of deal trends, key transactions, and active dealmakers
A trusted, evidence-based reference for vaccine dealmaking
Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how vaccine partnerships are structured, negotiated, and valued.

Product Code: CP2110

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in vaccine dealmaking

2.1. Introduction
2.2. Vaccine deals over the years
2.3. Most active vaccine dealmakers
2.4. Vaccine deals by deal type
2.5. Vaccine deals by therapy area
2.6. Vaccine deals by industry sector
2.7. Deal terms for vaccine deals
- 2.7.1 Vaccine deals headline values
- 2.7.2 Vaccine deal upfront payments
- 2.7.3 Vaccine deal milestone payments
- 2.7.4 Vaccine royalty rates

Chapter 3 - Leading vaccine deals

3.1. Introduction
3.2. Top vaccine deals by value

Chapter 4 - Most active vaccine dealmakers

4.1. Introduction
4.2. Most active vaccine dealmakers
4.3. Most active vaccine deals company profiles

Chapter 5 - Vaccine contracts dealmaking directory

5.1. Introduction
5.2. Vaccine contracts dealmaking directory

Chapter 6 - Vaccine dealmaking by technology type

Deal directory
Deal directory - Vaccine deals by company A-Z
Deal directory - Vaccine deals by deal type
Deal directory - Vaccine deals by therapy area
Deal type definitions
About Biopharma Research Ltd
Current Partnering
Current Agreements
Recent report titles from Current Partnering

Table of figures

Figure 1: Vaccine deals since 2016
Figure 2: Active vaccine dealmaking activity since 2016
Figure 3: Vaccine deals by deal type since 2016
Figure 4: Vaccine deals by therapy area since 2016
Figure 5: Vaccine deals by industry sector since 2016
Figure 6: Vaccine deals with a headline value
Figure 7: Vaccine deals with an upfront value
Figure 8: Vaccine deals with a milestone value
Figure 9: Vaccine deals with a royalty rate value
Figure 10: Top vaccine deals by value since 2016
Figure 11: Most active vaccine dealmakers since 2016
Figure 12: Vaccine deals by technology type since 2016